A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Muscular Atrophy, Spinal
In brief
The objectives of this trial are: to establish a safety profile for use of Hydroxyurea in children with Types II and III Spinal Muscular Atrophy; to identify reliable outcome measures for HU treatment in Types II and III SMA; and to detect the clinical efficacy of HU treatment in children with Types II and III SMA.
Key facts
- Study ID
- NCT00568802
- Run by
- Stanford University
- People needed
- 27
- Starts
- 2004-01-01
- Expected to finish
- 2010-03-01
- Last updated by the study team
- 2019-10-02
Who can join
Age: 1 and older, up to 10. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.